Get the Stockscreener App
1.15
0.00%
0.00
Sonoma Pharmaceuticals Inc stock is traded at $1.15, with a volume of 74,403.
It is up +0.00% in the last 24 hours and up +11.65% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$1.15
Open:
$1.16
24h Volume:
74,403
Relative Volume:
0.35
Market Cap:
$3.99M
Revenue:
$17.72M
Net Income/Loss:
$-3.37M
P/E Ratio:
-0.5643
EPS:
-2.038
Net Cash Flow:
$-3.72M
1W Performance:
+4.55%
1M Performance:
+11.65%
6M Performance:
-68.06%
1Y Performance:
-59.65%
1-Day Range:
$1.10
$1.18
1-Week Range:
$1.03
$1.26
52-Week Range:
$0.8501
$6.9199
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
1.15 | 3.99M | 17.72M | -3.37M | -3.72M | -2.038 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - TipRanks
Sonoma Pharmaceuticals Inc - TradingKey
Sonoma Pharmaceuticals boosts shelf offering capacity to $3.64M after prior $574.6K sales - TradingView
[8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth - TradingView
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - ACCESS Newswire
BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) outlines global HOCl strategy and risks - Stock Titan
SNOA Q1 2026 Earnings: EPS Misses Estimates Amid Operational and Revenue Disclosures - newsline.com
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals Q1 2026 Earnings: EPS Miss Triggers Sharp SelloffCFO Commentary Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Unchanged - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.13Channel Breakout - The Legal Advocate
SNOA Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains UnreportedEnergy Earnings Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Slightly Misses Estimates Amid Thin Revenue DisclosuresOne-Time Gain Impact - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Key Resistance at $1.13Volatility Smirk - Newser
SNOA SEC FilingsSonoma Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Sonoma Pharmaceuticals (SNOA) Slips -3.56%, Testing $1.08 Support 2026-05-15Fast Rising Stocks - Newser
Sonoma Pharmaceuticals (SNOA) Q1 2026 Earnings Miss by Significant: Key TakeawaysRevenue Guidance Update - Newser
SNOA Director Jacoby Vanessa Stock Option Filing, May 14, 2026 - Meyka
Sonoma Pharmaceuticals (SNOA) outlines plan to reincorporate from Delaware to Nevada - Stock Titan
Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital - The Globe and Mail
Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) closes $4M stock and warrant sale - Stock Titan
SNOA Sonoma Pharmaceuticals reports narrow Q1 2026 EPS miss as shares rise 1.92 percent on mild positive investor sentiment.Cost Advantage - Newser
SNOA Director Jacoby Vanessa Stock Option Filing, April 28, 2026 - Meyka
Sonoma Pharmaceuticals registers HOCl facial spray under U.S. cosmetics law - MSN
What's Going On With Sonoma Pharma Stock Monday? - Benzinga
2.96M-unit offering priced at $1.35 — Sonoma Pharmaceuticals (NASDAQ: SNOA) - Stock Titan
SNOA Drops As Sonoma Pharmaceuticals Launches Dilutive Offering - StocksToTrade
Sonoma Pharmaceuticals (SNOA) Secures $4M in Public Offering - GuruFocus
Sonoma Pharmaceuticals prices $4M stock offering at $1.35 per share - Investing.com
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering - ACCESS Newswire
[EFFECT] Sonoma Pharmaceuticals, Inc. SEC Filing - Stock Titan
Sonoma Pharmaceuticals (NASDAQ: SNOA) files S-1 for $5M unit and warrant sale - Stock Titan
SNOA (Sonoma Pharmaceuticals Inc.) Q1 2026 revenue growth drives 2.75 percent share gain despite narrow EPS miss.ROE - UBND thành phố Hải Phòng
SNOA Sonoma Pharmaceuticals shares jump 15 percent on 12 percent Q1 2026 revenue growth despite minor EPS miss.Crowd Entry Points - newser.com
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. announced the launch of a public offering, aiming to raise a total of $5 million through the issuance of units. - Exchange Bitget
Sonoma Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo
Sonoma Pharmaceuticals (NASDAQ: SNOA) plans $5M stock and warrant sale - Stock Titan
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.23%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):